X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (54) 54
xl184 (51) 51
humans (40) 40
cabozantinib (37) 37
oncology (32) 32
met (24) 24
cancer (23) 23
metastasis (23) 23
c-met (22) 22
animals (20) 20
pharmacology & pharmacy (19) 19
cabozantinib xl184 (18) 18
angiogenesis (17) 17
anilides - therapeutic use (15) 15
inhibitor (15) 15
pyridines - therapeutic use (15) 15
tumors (15) 15
anilides - pharmacology (14) 14
pyridines - pharmacology (14) 14
antineoplastic agents - therapeutic use (13) 13
thyroid cancer (13) 13
kinases (12) 12
medullary-thyroid cancer (12) 12
prostate cancer (12) 12
antineoplastic agents - pharmacology (11) 11
expression (11) 11
male (11) 11
sorafenib (11) 11
tyrosine (11) 11
vascular endothelial growth factor (11) 11
kidney neoplasms - drug therapy (10) 10
pharmacokinetics (10) 10
proto-oncogene proteins c-met - antagonists & inhibitors (10) 10
proto-oncogene proteins c-met - metabolism (10) 10
renal cell carcinoma (10) 10
tyrosine kinase inhibitor (10) 10
vegfr2 (10) 10
analysis (9) 9
carcinoma, renal cell - drug therapy (9) 9
care and treatment (9) 9
cell line, tumor (9) 9
clinical trials (9) 9
female (9) 9
mice (9) 9
phase-ii (9) 9
protein kinase inhibitors - pharmacology (9) 9
protein kinase inhibitors - therapeutic use (9) 9
ret (9) 9
targeted therapy (9) 9
therapy (9) 9
thyroid neoplasms - drug therapy (9) 9
tumor-growth (9) 9
anilides - pharmacokinetics (8) 8
article (8) 8
cancer therapies (8) 8
carcinoma (8) 8
drug therapy (8) 8
everolimus (8) 8
growth (8) 8
medical prognosis (8) 8
medicine & public health (8) 8
middle aged (8) 8
open-label (8) 8
pyridines - pharmacokinetics (8) 8
anilides - administration & dosage (7) 7
double-blind (7) 7
inhibitors (7) 7
mutation (7) 7
patients (7) 7
pharmacology/toxicology (7) 7
phase-ii trial (7) 7
pyridines - administration & dosage (7) 7
research (7) 7
sunitinib (7) 7
tyrosine kinase (7) 7
vegf (7) 7
xenograft model antitumor assays (7) 7
adult (6) 6
anilides - adverse effects (6) 6
antineoplastic agents - adverse effects (6) 6
chemotherapy (6) 6
clinical trials as topic (6) 6
dose-response relationship, drug (6) 6
endothelial growth-factor (6) 6
fda approval (6) 6
medullary thyroid cancer (6) 6
protein-tyrosine kinase (6) 6
pyridines - adverse effects (6) 6
receptor (6) 6
receptor protein-tyrosine kinases - antagonists & inhibitors (6) 6
signal transduction - drug effects (6) 6
treatment outcome (6) 6
aged (5) 5
apoptosis - drug effects (5) 5
biochemistry & molecular biology (5) 5
carcinoma, renal cell (5) 5
cell proliferation - drug effects (5) 5
chemistry, medicinal (5) 5
hepatocyte growth-factor (5) 5
in-vivo (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1814 - 1823
Journal Article
Molecular cancer research : MCR, ISSN 1541-7786, 02/2019, Volume 17, Issue 2, pp. 499 - 507
Osimertinib (AZD9291) has an efficacy superior to that of standard EGFR-tyrosine kinase inhibitors for the first-line treatment of patients with EGFR-mutant... 
THERAPY | CABOZANTINIB XL184 | ONCOLOGY | STATISTICS | MUTATION | OPEN-LABEL | PATIENT | INHIBITORS | MET | RECEPTOR TYROSINE KINASE | AZD9291 | CELL BIOLOGY
Journal Article
Oncogene, ISSN 0950-9232, 05/2016, Volume 35, Issue 21, pp. 2687 - 2697
Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell carcinoma (RCC). The purpose of this study was to understand the... 
ACTIVATION | METASTASIS | ANGIOGENESIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | CANCER | CELL BIOLOGY | RECEPTOR TYROSINE KINASES | CABOZANTINIB XL184 | ONCOLOGY | C-MET | GROWTH | GENETICS & HEREDITY | EXPRESSION | PROGRESSION | Proto-Oncogene Proteins c-met - metabolism | Humans | Drug Resistance, Neoplasm | Molecular Targeted Therapy | Sunitinib | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Carcinoma, Renal Cell - enzymology | Indoles - pharmacology | Carcinoma, Renal Cell - drug therapy | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Signal Transduction | Carcinoma, Renal Cell - pathology | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Proto-Oncogene Proteins - genetics | Receptor Protein-Tyrosine Kinases - metabolism | Proto-Oncogene Proteins c-met - genetics | Xenograft Model Antitumor Assays | Pyrroles - pharmacology | Animals | Receptor Protein-Tyrosine Kinases - genetics | Mice, Nude | Kidney Neoplasms - enzymology | Kidney Neoplasms - pathology | Cell Proliferation - drug effects | Mice | Kidney Neoplasms - drug therapy | Molecular targeted therapy | Genetic aspects | Carcinoma, Renal cell | Drug therapy | Drug resistance | Properties | Phosphotransferases | Methods | Cancer therapies | Kidney cancer | Metastasis | Index Medicus | Cabozantinib | Renal Cell Carcinoma | AXL | MET
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 50, pp. 87891 - 87902
The tumor microenvironment (TME) is increasingly recognized as the arbiter of metastatic progression and drug resistance in advanced prostate cancer (PCa).... 
Cabozantinib | Carcinoma associated fibroblasts | Metastasis | Prostate cancer | CELLS | XL184 | SUPPRESSION | CANCER | cabozantinib | CELL BIOLOGY | BRAF INHIBITION | prostate cancer | metastasis | GROWTH | carcinoma associated fibroblasts | BONE | MET
Journal Article
Cancer Research, ISSN 0008-5472, 07/2011, Volume 71, Issue 14, pp. 4758 - 4768
Angiogenesis inhibitors that block VEGF receptor (VEGFR) signaling slow the growth of many types of tumors, but eventually the disease progresses. Multiple... 
BREAST-CANCER | INVASIVE GROWTH | METASTASIS | ONCOLOGY | TYROSINE KINASE | IN-VIVO | THERAPEUTIC TARGET | TUMOR-GROWTH | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | SMALL-MOLECULE INHIBITOR | Proto-Oncogene Proteins c-met - metabolism | Basement Membrane - drug effects | Vascular Endothelial Growth Factor Receptor-3 - biosynthesis | Adenoma, Islet Cell - pathology | Apoptosis - drug effects | Pancreatic Neoplasms - blood supply | Adenoma, Islet Cell - blood supply | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Basement Membrane - pathology | Quinolines - pharmacology | Neovascularization, Pathologic - pathology | Pancreatic Neoplasms - drug therapy | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Adenoma, Islet Cell - drug therapy | Vascular Endothelial Growth Factor Receptor-2 - biosynthesis | Cell Hypoxia - drug effects | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Mice, Inbred C57BL | Pancreatic Neoplasms - pathology | Basement Membrane - metabolism | Animals | Neovascularization, Pathologic - drug therapy | Anilides - pharmacology | Mice | Neovascularization, Pathologic - metabolism | Pyridines - pharmacology | Vascular Endothelial Growth Factor Receptor-3 - antagonists & inhibitors | Index Medicus | RIP-Tag2 mice | receptor tyrosine kinases | VEGF | XL184 (cabozantinib) | c-Met | Angiogenesis inhibitors | XL999 | XL880 (foretinib, GSK1363089)
Journal Article
Future Oncology, ISSN 1479-6694, 08/2013, Volume 9, Issue 8, pp. 1083 - 1092
Cabozantinib (XL184) is an oral multiple receptor tyrosine kinase inhibitor manufactured by Exelixis Inc., CA, USA. It mainly inhibits three tyrosine kinase... 
advanced medullary thyroid cancer | XL184 | tyrosine kinase inhibitor | BMS-907351 | cabozantinib | RET | FOLLOW-UP | PREVALENCE | CHEMOTHERAPY | ONCOLOGY | RAS MUTATIONS | INHIBITOR | CARCINOMA | EXPRESSION | MET | ENDOTHELIAL GROWTH-FACTOR
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2015, Volume 55, Issue 9, pp. 1012 - 1023
Cabozantinib is a small-molecule tyrosine kinase inhibitor that has been approved for the treatment of patients with progressive, metastatic medullary thyroid... 
pharmacokinetics | CYP2C8 | drug–drug interaction | CYP3A4 | cabozantinib | drug-drug interaction | XL184 | ERYTHROMYCIN | SUNITINIB | PHARMACOLOGY & PHARMACY | SORAFENIB | 6-BETA-HYDROXYCORTISOL | Rifampin - pharmacokinetics | Area Under Curve | Ketoconazole - administration & dosage | Humans | Microsomes, Liver - metabolism | Half-Life | Pyridines - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Anilides - pharmacokinetics | Antineoplastic Agents - administration & dosage | Thiazolidinediones - pharmacokinetics | Hypoglycemic Agents - blood | Drug Interactions | Cytochrome P-450 CYP3A Inducers - pharmacokinetics | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacokinetics | Microsomes, Liver - enzymology | Cytochrome P-450 CYP2C8 - metabolism | Rifampin - administration & dosage | Hypoglycemic Agents - pharmacokinetics | Pyridines - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - blood | Ketoconazole - pharmacokinetics | Anilides - blood | Cytochrome P-450 CYP3A Inducers - administration & dosage | Pyridines - blood | Anilides - administration & dosage | Antineoplastic Agents - blood | Thiazolidinediones - blood | Dosage and administration | Ketoconazole | Pharmacokinetics | Rifampin | Analysis | Drug interactions | Plasma | Index Medicus
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2011, Volume 17, Issue 12, pp. 3943 - 3955
Journal Article